The World Health Organization (WHO) announced the availability of 70,000 doses of the Ervebo vaccine. This batch includes 20,000 doses designated for a Phase 3 clinical trial, aimed at analyzing the vaccine's effect against the Bundibugyo virus, and 50,000 doses reserved for healthcare professionals and frontline workers.
Although there is no confirmation yet that the Ervebo vaccine, which was specifically approved for the Zaire strain of the Ebola virus, can protect against the Bundibugyo virus, initial data obtained in laboratories and animals indicate that it may offer some protection.
The epidemiological situation in the Democratic Republic of Congo (DRCongo) is serious, with the outbreak having already caused 2,476 deaths and recorded 5,208 confirmed cases, according to data released today by the government of Kinshasa. This establishes this Ebola outbreak as the deadliest ever documented.
In a meeting of the Emergency Committee, convened under the International Health Regulations to assess the epidemic, the WHO Director-General, Tedros Adhanom Ghebreyesus, warned that the epidemic is far from being controlled. He stressed that the risk of wider dissemination within the DRCongo and to other nations remains high.
Adhanom Ghebreyesus stated three months ago that the epidemic caused by the Bundibugyo virus in the DRCongo constituted a public health emergency of international concern. He added that since then, the disease has spread rapidly, keeping the risk of national and international propagation high.
According to recent WHO information, the Ebola virus began circulating in the eastern region of the DRCongo in February. However, a study published in the journal Science at the end of July hypothesized that the first infections might have occurred even earlier, possibly in January.
After the declaration of the epidemic in the Ituri province, the virus spread to neighboring Uganda. This country had declared itself Ebola-free on July 28, after recording 20 confirmed cases, 15 of which were classified as imported from the DRCongo, including two deaths.
The current epidemic is linked to the Bundibugyo strain, characterized by a fatality rate ranging between 30% and 50%. The WHO reports that there is no authorized vaccine or specific treatment for this strain.
The Ebola virus is transmitted through direct contact with the body fluids of infected individuals or animals and manifests with severe hemorrhagic fever, vomiting, diarrhea, and internal bleeding.

